Charles River partners with CRO to expand PDX model capabilities
Charles River Laboratories International, Inc. has partnered with OcellO to expand its PDX model capabilities and has made several additions to its online Tumor Model Compendium.
Archives for May 21, 2017
US triples indications for Kalydeco without needing new clinical data
The US FDA has approved Vertex’s cystic fibrosis drug Kalydeco (ivacaftor) to treat a further 23 genetic mutations based solely on in vitro data.
EMA committee says AB Science’s Masitinib should not be approved in light of GCP failings
AB Science’s candidate cancer drug Masitinib (masitinib) should not be approved according to an EMA committee, which cited concerns about data and failings identified in a 2015 trial.
CRO partners with humanized model developer to advance liver disease research
Seventh Wave Laboratories and Yecuris Corporation have announced an exclusive collaboration through which the CRO will provide various services.
Report: CRO turnover creates loss of continuity
Contract research organizations (CROs) continue to see high instances of turnover, which can lead to delayed timelines and sponsor scrutiny, according to a recent survey.
Synlogic takeover secures Mirna’s NASDAQ listing + $40m cash
Synlogic has announced it will conduct a reverse merger with failed Mirna Therapeutics, to focus on metabolic and inflammatory diseases and cancer.
Aduro and Merck & Co to test Keytruda and CRS-207 in second cancer study
Merck & Co and Aduro Biotech have announced plans to test Keytruda combined with CRS-207 in patients suffering malignant pleural mesothelioma as a result of exposure to asbestos.